Long COVID
Conditions
Brief summary
This study will use a prospective, open, single-arm design, in which a group of 100 patients with a diagnosis of prolonged COVID, previously selected according to inclusion and exclusion criteria, and who have undergone informed consent process and have signed the informed consent form, undergo two hemoperfusion procedures with the Seraph 100 filter, on consecutive days. They are then evaluated at day 3 and 4 weeks, to complete the safety and effectiveness assessment.
Detailed description
This will be a prospective, open-label, single-arm, pilot study, in which a group of 100 PC patients will undergo two hemoperfusion procedures, to verify the safety and preliminary efficacy of the Seraph 100 device. Eligible patients will be invited to participate and once they sign the Informed Consent (IC) they will undergo two hemoperfusion procedures, on consecutive days, of -4 hours duration each time, using a multicomponent apheresis machine with the Seraph 100 filter. Patients will be followed for a total of 30 days, to monitor the presence of AEs (safety) and possible changes in clinical outcomes (preliminary efficacy).
Interventions
DEVICESeraph® 100 Microbind® Affinity Blood Filter (Seraph 100)
The Seraph 100 is part of the Seraph platform technology that was developed as an extracorporeal broad-spectrum sorbent hemoperfusion device for reduction of pathogens, bacteria, viruses, fungus, and other sepsis mediators from the bloodstream. In addition, it has been demonstrated that Seraph 100 is also capable of removing circulating tumor cells from the whole blood.
Sponsors
ExThera Medical Corporation
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Masking description
Unblinded
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
Subjects will be considered eligible for participation in the study if they meet all the following inclusion criteria: 1. Adult patients age of 18-85 (had 18th birthday but did not have 85th birthday). 2. History of COVID 19 infection established by positive polymerase chain reaction (PCR) test or by compatible clinical testing (e.g. rapid antigen, serum testing, or other relevant clinical documentation). 3. Persistent symptoms for 12 or more weeks after acute COVID 19 infection including fatigue and one or more of the following: myalgia or generalized aches and pains; joint pain; dizziness or unsteadiness; cognitive dysfunction (mental fog). 4. Patient (legally designated representative) has completed the Informed Consent process prior to enrollment into this study. 5. Patient (legally designated representative) is willing to comply with the study protocol -
Exclusion criteria
Subjects meeting any of the following criteria will not be recruited for the study: 1. History of heparin allergy. 2. History of heparin-induced thrombocytopenia. 3. Pregnancy or breastfeeding. 4. Life expectancy is less than 30 days. 5. The patient is currently enrolled in another drug or device trial. Patients who cannot tolerate placement of double-lumen catheter. 6. Unable to obtain informed consent from either patient or legally authorized representative (LAR)Any subject who, in the investigator's judgment, is considered unsuitable for participation in this trial. After verification of eligibility and signature of consent: 1\. The patient must be able to perform a hemoperfusion procedure with an apheresis machine.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of Technical Procedure Success | Procedure Stop Time | Procedural Success is defined as: 1. Device use as originally intended, and 2. No device procedure related serious adverse events (SAEs) |
| Assessment of Device Success | 3, 7 and 28 days | Seraph 100 Device Success |
Countries
Mexico
Contacts
PRINCIPAL_INVESTIGATORMink Chawla, M.D.
ExThera Medical Corporation
Outcome results
None listed